Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6432198rdf:typepubmed:Citationlld:pubmed
pubmed-article:6432198lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:6432198lifeskim:mentionsumls-concept:C0009782lld:lifeskim
pubmed-article:6432198lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:6432198lifeskim:mentionsumls-concept:C0022616lld:lifeskim
pubmed-article:6432198lifeskim:mentionsumls-concept:C0034735lld:lifeskim
pubmed-article:6432198pubmed:issue6445lld:pubmed
pubmed-article:6432198pubmed:dateCreated1984-10-22lld:pubmed
pubmed-article:6432198pubmed:abstractTextThe serotonin receptor blocker ketanserin was given orally in a double blind crossover study to 10 patients with connective tissue disorders and Raynaud's phenomenon. Eight of the 10 patients improved clinically on ketanserin and none on placebo. Digital blood flow was assessed with laser Doppler flowmetry (LDF), photoplethysmography, and skin temperature measurements. Laser Doppler flowmetry was the most useful method, showing a significant reduction in recovery time after a standard cold provocation. Although the resting flow was not significantly improved, digital ulcers healed in four out of five patients, providing evidence of increased nutritive flow. The results of this study suggest that orally administered ketanserin may be an effective and well tolerated treatment for Raynaud's phenomenon associated with connective tissue disorders, especially scleroderma.lld:pubmed
pubmed-article:6432198pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6432198pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6432198pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6432198pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6432198pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6432198pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6432198pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6432198pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6432198pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6432198pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6432198pubmed:languageenglld:pubmed
pubmed-article:6432198pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6432198pubmed:citationSubsetAIMlld:pubmed
pubmed-article:6432198pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6432198pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6432198pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6432198pubmed:statusMEDLINElld:pubmed
pubmed-article:6432198pubmed:monthSeplld:pubmed
pubmed-article:6432198pubmed:issn0267-0623lld:pubmed
pubmed-article:6432198pubmed:authorpubmed-author:SeemEElld:pubmed
pubmed-article:6432198pubmed:authorpubmed-author:RoaldO KOKlld:pubmed
pubmed-article:6432198pubmed:issnTypePrintlld:pubmed
pubmed-article:6432198pubmed:day8lld:pubmed
pubmed-article:6432198pubmed:volume289lld:pubmed
pubmed-article:6432198pubmed:ownerNLMlld:pubmed
pubmed-article:6432198pubmed:authorsCompleteYlld:pubmed
pubmed-article:6432198pubmed:pagination577-9lld:pubmed
pubmed-article:6432198pubmed:dateRevised2009-11-18lld:pubmed
pubmed-article:6432198pubmed:meshHeadingpubmed-meshheading:6432198-...lld:pubmed
pubmed-article:6432198pubmed:meshHeadingpubmed-meshheading:6432198-...lld:pubmed
pubmed-article:6432198pubmed:meshHeadingpubmed-meshheading:6432198-...lld:pubmed
pubmed-article:6432198pubmed:meshHeadingpubmed-meshheading:6432198-...lld:pubmed
pubmed-article:6432198pubmed:meshHeadingpubmed-meshheading:6432198-...lld:pubmed
pubmed-article:6432198pubmed:meshHeadingpubmed-meshheading:6432198-...lld:pubmed
pubmed-article:6432198pubmed:meshHeadingpubmed-meshheading:6432198-...lld:pubmed
pubmed-article:6432198pubmed:meshHeadingpubmed-meshheading:6432198-...lld:pubmed
pubmed-article:6432198pubmed:meshHeadingpubmed-meshheading:6432198-...lld:pubmed
pubmed-article:6432198pubmed:meshHeadingpubmed-meshheading:6432198-...lld:pubmed
pubmed-article:6432198pubmed:meshHeadingpubmed-meshheading:6432198-...lld:pubmed
pubmed-article:6432198pubmed:meshHeadingpubmed-meshheading:6432198-...lld:pubmed
pubmed-article:6432198pubmed:meshHeadingpubmed-meshheading:6432198-...lld:pubmed
pubmed-article:6432198pubmed:meshHeadingpubmed-meshheading:6432198-...lld:pubmed
pubmed-article:6432198pubmed:meshHeadingpubmed-meshheading:6432198-...lld:pubmed
pubmed-article:6432198pubmed:year1984lld:pubmed
pubmed-article:6432198pubmed:articleTitleTreatment of Raynaud's phenomenon with ketanserin in patients with connective tissue disorders.lld:pubmed
pubmed-article:6432198pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6432198pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:6432198pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:6432198pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6432198lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6432198lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6432198lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6432198lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6432198lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6432198lld:pubmed